Brennan Aoife 4

What Happened

• Brennan Aoife, President, CEO and Director of Climb Bio (CLYM), had 68,750 restricted stock units (RSUs) convert into 68,750 shares on June 27, 2026. The filing shows those converted shares were net-settled/withheld (reported as a derivative disposition at $0) to cover withholding obligations. On June 29, 2026 she sold 30,902 shares in the open market for a weighted average price of $13.17, generating $406,979 in proceeds.
• The RSUs were originally granted June 27, 2024 and vest over four years (25% each year), so the 68,750 shares represent the scheduled annual vesting tranche. The sale was executed under a pre-existing 10b5-1 plan to cover tax withholding tied to the RSU vesting.

Key Details

• Transaction dates/prices: RSU conversion 6/27/2026 (68,750 shares); net settlement/withholding reported as disposed at $0; open-market sale 6/29/2026 — 30,902 shares at a weighted avg $13.17 (range $13.02–$13.34), proceeds $406,979.
• Shares owned after transaction: not specified in the Form 4.
• Notable footnotes: sale was pursuant to a 10b5-1 trading plan adopted Aug 30, 2024 to cover tax withholding; each RSU converts to one share; total holdings reported include an additional 1,751 shares from the company ESPP.
• Filing timeliness: Form 4 filed 2026-06-30 for transactions on 6/27 and 6/29 (filing indicates timely reporting).

Context

• The June 27 conversion was an RSU settlement (not an option exercise requiring cash); the $0 disposition and the separate open-market sale indicate net settlement/withholding plus a 10b5-1 sale to cover tax obligations — a common routine practice when equity awards vest.
• This filing documents routine award vesting and associated tax-related selling, not an independent purchase signal.